Antithrombotic strategies for preventing graft failure in coronary artery bypass graft

Area of Science:

• Cardiovascular Surgery
• Pharmacology
• Clinical Trials

Background:

• Coronary artery bypass grafting (CABG) is challenged by graft failure due to thrombosis, hyperplasia, and atherosclerosis.
• Optimal antithrombotic therapy post-CABG is uncertain, lacking definitive guidelines and relying on expert opinion.
• Graft occlusion significantly impacts long-term patient outcomes after CABG.

Purpose of the Study:

• To review randomized clinical trials and meta-analyses on antithrombotic therapy in CABG patients.
• To evaluate the efficacy and safety of various antithrombotic regimens for preventing graft failure.
• To inform clinical decision-making regarding antithrombotic strategies after CABG.

Main Methods:

• Systematic review of randomized clinical trials and meta-analyses.
• Analysis of antithrombotic strategies including single antiplatelet therapy (aspirin, P2Y12 inhibitors), dual antiplatelet therapy, and anticoagulation.
• Evaluation of graft patency, major adverse cardiovascular events, and bleeding complications.

Main Results:

• Aspirin is established as a cornerstone of post-CABG antithrombotic therapy.
• Adding P2Y12 inhibitors to aspirin has shown mixed results in randomized controlled trials.
• The optimal balance between preventing graft occlusion and minimizing bleeding risk requires further investigation.

Conclusions:

• Current evidence on optimal antithrombotic strategies post-CABG is inconclusive.
• Further research is needed to establish definitive guidelines for antithrombotic therapy after CABG.
• Personalized antithrombotic approaches may be necessary to optimize long-term CABG outcomes.